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Background
The preferred initial treatment for patients with stable coronary artery disease is the 
best available medical therapy. We hypothesized that in patients with functionally 
significant stenoses, as determined by measurement of fractional flow reserve (FFR), 
percutaneous coronary intervention (PCI) plus the best available medical therapy 
would be superior to the best available medical therapy alone.
Methods
In patients with stable coronary artery disease for whom PCI was being considered, 
we assessed all stenoses by measuring FFR. Patients in whom at least one stenosis 
was functionally significant (FFR, ≤0.80) were randomly assigned to FFR-guided 
PCI plus the best available medical therapy (PCI group) or the best available medical 
therapy alone (medical-therapy group). Patients in whom all stenoses had an FFR of 
more than 0.80 were entered into a registry and received the best available medical 
therapy. The primary end point was a composite of death, myocardial infarction, or 
urgent revascularization.
Results
Recruitment was halted prematurely after enrollment of 1220 patients (888 who 
underwent randomization and 332 enrolled in the registry) because of a significant 
between-group difference in the percentage of patients who had a primary end-
point event: 4.3% in the PCI group and 12.7% in the medical-therapy group (hazard 
ratio with PCI, 0.32; 95% confidence interval [CI], 0.19 to 0.53; P<0.001). The dif-
ference was driven by a lower rate of urgent revascularization in the PCI group than 
in the medical-therapy group (1.6% vs. 11.1%; hazard ratio, 0.13; 95% CI, 0.06 to 0.30; 
P<0.001); in particular, in the PCI group, fewer urgent revascularizations were trig-
gered by a myocardial infarction or evidence of ischemia on electrocardiography 
(hazard ratio, 0.13; 95% CI, 0.04 to 0.43; P<0.001). Among patients in the registry, 
3.0% had a primary end-point event.
Conclusions
In patients with stable coronary artery disease and functionally significant stenoses, 
FFR-guided PCI plus the best available medical therapy, as compared with the best 
available medical therapy alone, decreased the need for urgent revascularization. In 
patients without ischemia, the outcome appeared to be favorable with the best 
available medical therapy alone. (Funded by St. Jude Medical; ClinicalTrials.gov 
number, NCT01132495.)
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Percutaneous coronary interven-tion (PCI) improves the outcome in patients with acute coronary syndromes.1 In contrast, 
for the treatment of patients with stable coronary 
artery disease, controversy persists regarding the 
extent of the benefit from PCI, as compared with 
the best available medical therapy, as an initial 
management strategy.2-5 The potential benefit of 
revascularization depends on the presence and 
extent of myocardial ischemia.6-8 Performing PCI 
on nonischemic stenoses is not beneficial9 and is 
probably harmful.10 Thus, careful selection of 
ischemia-inducing stenoses is essential for deriv-
ing the greatest benefit from revascularization in 
patients with stable coronary artery disease.
Fractional flow reserve (FFR) is a pressure-
wire–based index that is used during coronary 
angiography to assess the potential of a coronary 
stenosis to induce myocardial ischemia.11-14 The 
usefulness of FFR-guided PCI as compared with 
PCI guided by angiography alone is supported by 
robust clinical outcome data.9,10,14-17
The aim of this trial was to determine whether 
FFR-guided PCI with drug-eluting stents plus the 
best available medical therapy is superior to the 
best available medical therapy alone in reducing 
the rate of death, myocardial infarction, or un-
planned hospitalization leading to urgent revascu-
larization among patients with stable coronary 
artery disease.
Me thods
Study Design and Oversight
The Fractional Flow Reserve versus Angiography 
for Multivessel Evaluation 2 (FAME 2) study is a 
randomized “all comers” trial (i.e., involving the 
consecutive enrollment of all eligible patients 
with stable coronary artery disease). The trial 
was conducted at 28 sites in Europe and North 
America and was approved by the institutional 
review board at each participating center. The 
members of the steering committee (see the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org) designed the study with-
out involvement of the sponsor, St. Jude Medical. 
The sponsor was involved in the collection and 
source verification of the data but not in the con-
duct of the trial or in the decision to terminate it. 
An independent data and safety monitoring 
board (see the Supplementary Appendix) oversaw 
the trial and met twice a year or more frequently, 
as necessary for the oversight of the trial. No for-
mal stopping rules were specified. The academic 
members of the steering committee had full ac-
cess to all the data in the study, vouch for the 
accuracy and completeness of the data and analy-
ses and for the fidelity of the study to the proto-
col, wrote the manuscript, and had final respon-
sibility for the decision to submit it for publication. 
The research protocol is available at NEJM.org.
Patients
Patients in stable condition who were appropriate 
candidates for PCI and who had angiographically 
assessed one-, two-, or three-vessel coronary ar-
tery disease suitable for PCI were included in the 
trial. Details of the inclusion and exclusion crite-
ria are provided in the Supplementary Appendix. 
The investigator first indicated which stenoses were 
thought to require stenting on the basis of the 
clinical and angiographic data. FFR was then mea-
sured with a coronary guidewire (PressureWire 
Certus or PressureWire Aeris, St. Jude Medical) 
during adenosine-induced hyperemia to assess 
the hemodynamic severity of each indicated ste-
nosis. Patients who had at least one stenosis in a 
major coronary artery with an FFR of 0.80 or less 
were randomly assigned, by means of an interac-
tive voice-response system, to FFR-guided PCI plus 
the best available medical therapy (hereinafter 
called the PCI group) or to the best available med-
ical therapy alone (hereinafter called the medical-
therapy group). The randomization schedule was 
computer-generated; randomization was strati-
fied according to site and performed in blocks, 
with block sizes varied randomly. Patients with 
an FFR of more than 0.80 in all vessels with indi-
cated stenoses were enrolled in a registry and 
received the best available medical therapy. A 
random sample of 50% of the registry patients 
underwent the same follow-up as the patients in 
the randomized trial. The treatment assignments 
were known to the patients. All patients provided 
written informed consent.
Treatment
All patients were prescribed aspirin at a dose of 
80 to 325 mg daily, metoprolol at a dose of 50 to 
200 mg daily (or any other beta-1–selective blocker, 
alone or in combination with a calcium-channel 
blocker or a long-acting nitrate), lisinopril (≥5 mg 
daily, or another angiotensin-converting–enzyme 
[ACE] inhibitor or an angiotensin II–receptor 
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blocker if the patient had unacceptable side ef-
fects with the ACE inhibitor), and atorvastatin 
(20 to 80 mg daily, or another statin of similar 
potency alone or in combination with ezetimibe, to 
reduce the low-density-lipoprotein [LDL] level to 
less than 70 mg per deciliter [1.8 mmol per liter]).
Patients who were randomly assigned to PCI 
received a loading dose of clopidogrel (600 mg) 
and aspirin immediately before the procedure if 
they were not already taking these medications. All 
stenoses with an FFR of 0.80 or less were treated 
with second-generation drug-eluting stents.18-20 
After PCI, all patients received clopidogrel at a 
dose of 75 mg per day for at least 12 months in 
addition to the best available medical therapy. All 
patients were given a medication tracking form 
for recording weekly medication use and doses. 
Patients who smoked were counseled regarding 
smoking cessation. Patients with diabetes were 
referred to a diabetes specialist to receive the 
best available treatment for that disease.
Follow-up
Electrocardiography (ECG) was performed with the 
patient at rest, and the creatine kinase level and 
the MB fraction of creatine kinase were measured 
in all patients before angiography was performed 
and between 12 and 24 hours after enrollment. 
Follow-up visits were scheduled at 1 and 6 months 
and at 1, 2, 3, 4, and 5 years. At baseline and all 
follow-up visits, we obtained information regard-
ing the presence or absence (and, if present, the 
severity) of angina, the patient’s work status, and 
the number and doses of cardiac medications and 
assessed the patient’s quality of life with the use 
of the European Quality of Life–5 Dimensions 
[EQ-5D] instrument.21 In addition, we performed 
resting ECG, measured the levels of total choles-
terol and cholesterol fractions, and assessed the 
patient’s utilization of medical resources.
End Points
The prespecified primary end point was a compos-
ite of death from any cause, nonfatal myocardial 
infarction, or unplanned hospitalization leading to 
urgent revascularization during the first 2 years. 
Secondary end points included individual com-
ponents of the primary end point, cardiac death, 
nonurgent revascularization, and angina class. 
All outcomes were adjudicated by an independent 
clinical events committee (see the Supplementary 
Appendix) whose members were unaware of the 
treatment assignments. For each revasculariza-
tion procedure, a detailed description was in-
cluded. Revascularization was considered to be 
urgent when a patient was admitted to the hospi-
tal with persistent or increasing chest pain (with 
or without ST-segment or T-wave changes or ele-
vated biomarker levels) and the revascularization 
procedure was performed during the same hos-
pitalization.
Statistical Analysis
The trial was powered to determine whether PCI 
with the best available medical therapy was supe-
rior to the best available medical therapy alone with 
respect to the primary end point at 24 months. 
On the basis of findings from previous studies and 
using binomial proportions, we estimated that the 
cumulative incidence of the primary end point at 
24 months would be 12.6% in the PCI group18-20 
and 18.0% in the medical-therapy group,3 corre-
sponding to a relative risk reduction with PCI of 
30%, and that with 816 patients in each group, 
the study would have more than 84% power to 
detect that relative risk reduction, at a two-sided 
type I error rate of 0.05. Continuous variables are 
presented as means and standard deviations, and 
categorical data are presented as numbers and per-
centages. All patients were included in the analy sis 
according to the groups to which they were orig-
inally assigned (intention-to-treat analysis). We 
used the Mantel–Cox method to calculate hazard 
ratios and 95% confidence intervals for the be-
tween-group comparisons of clinical outcomes 
and the log-rank test to calculate corresponding 
P values. We constructed Kaplan–Meier curves for 
the primary end point and its components. 
In an exploratory analysis, we also calculated 
the hazard ratio for urgent revascularization 
triggered by a myocardial infarction or by un-
stable angina with evidence of ischemia on ECG. 
We used a chi-square test to assess the interac-
tion between treatment effect and these charac-
teristics. Landmark analyses were performed 
according to a landmark point at 7 days, with 
the hazard ratio calculated separately for events 
that occurred up to 7 days after randomization 
and events that occurred between 8 days and the 
end of the follow-up period. We then performed 
a test for the interaction between treatment and 
time (first 7 days vs. subsequent period). In all 
time-to-event analyses (i.e., overall and land-
mark), for each type of event, data for a patient 
The New England Journal of Medicine 
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Table 1. Baseline Clinical, Angiographic, and Fractional Flow Reserve (FFR) Characteristics.*
Variable Randomly Assigned Groups Registry Cohort P Value†
PCI plus Medical 
Therapy
Medical Therapy 
Alone
Patient characteristics
Total no. of patients 447 441 166
Age — yr 63.52±9.35 63.86±9.62 63.58±9.75 0.90
Male sex — no. (%) 356 (79.6) 338 (76.6) 113 (68.1) 0.005
Body-mass index‡ 28.29±4.27 28.44±4.55 27.83±3.94 0.14
Family history of coronary artery disease — no. (%) 216 (48.3) 207 (46.9) 76 (45.8) 0.65
Current smoking — no. (%) 89 (19.9) 90 (20.4) 35 (21.1) 0.79
Hypertension — no. (%) 347 (77.6) 343 (77.8) 136 (81.9) 0.23
Hypercholesterolemia — no. (%) 330 (73.8) 348 (78.9) 118 (71.1) 0.15
Diabetes mellitus — no. (%)
Any 123 (27.5) 117 (26.5) 42 (25.3) 0.65
Insulin-dependent 39 (8.7) 39 (8.8) 10 (6.0) 0.24
Renal insufficiency — no. (%)§ 8 (1.8) 12 (2.7) 7 (4.2) 0.14
Peripheral vascular disease — no. (%) 43 (9.6) 47 (10.7) 8 (4.8) 0.03
History of stroke or transient ischemic attack — no. (%) 33 (7.4) 28 (6.3) 10 (6.0) 0.69
History of myocardial infarction — no./total no. (%) 164/442 (37.1) 165/436 (37.8) 60/164 (36.6) 0.83
History of PCI in target vessel — no. (%) 80 (17.9) 76 (17.2) 34 (20.5) 0.37
Angina — no./total no (%)¶ 0.64
Asymptomatic 53/447 (11.9) 46/440 (10.5) 17/166 (10.2)
CCS class I 82/447 (18.3) 98/440 (22.3) 42/166 (25.3)
CCS class II 204/447 (45.6) 197/440 (44.8) 74/166 (44.6)
CCS class III 80/447 (17.9) 65/440 (14.8) 23/166 (13.9)
CCS class IV, stabilized 28/447 (6.3) 34/440 (7.7) 10/166 (6.0)
Silent ischemia — no. (%) 73 (16.3) 73 (16.6) 27 (16.3) 0.96
Left ventricular ejection fraction <50% — no./total no. (%) 83/423 (19.6) 56/410 (13.7) 27/150 (18.0) 0.69
Angiographic findings
Angiographically significant lesions — no. per patient 1.87±1.05 1.73±0.94 1.32±0.59 <0.001
Vessels with at least one significant lesion  
— no. of patients (%)
<0.001
1 251 (56.2) 261 (59.2) 136 (81.9)
2 156 (34.9) 146 (33.1) 26 (15.7)
3 40 (8.9) 34 (7.7) 4 (2.4)
At least one significant lesion in proximal or middle left anterior 
descending artery — no. (%)
291 (65.1) 276 (62.6) 74 (44.6) <0.001
FFR findings
Functionally significant lesions — no. per patient 1.52±0.78 1.42±0.73 0.03±0.17 <0.001
Vessels with at least one significant lesion — no. of patients (%) <0.001
1 331 (74.0) 343 (77.8) 5 (3.0)‖
2 102 (22.8) 85 (19.3) 0
3 14 (3.1) 13 (2.9) 0
At least one significant lesion in proximal or middle left anterior 
descending artery — no. (%)
279 (62.4) 263 (59.6) 1 (0.6) <0.001
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were censored at the time of the first event that 
occurred in that patient. All analyses were per-
formed by an independent statistician from an 
academic clinical trials unit (CTU Bern, Univer-
sity of Bern, Switzerland) with the use of Stata 
software, version 11.2.
R esult s
Study Termination and Patient Follow-up
At the recommendation of the independent data 
and safety monitoring board, patient recruitment 
was stopped on January 15, 2012, owing to a high-
ly significant difference in the incidence rates of 
the primary end point between the PCI and med-
ical-therapy groups. Between May 15, 2010, and 
January 15, 2012, a total of 1220 patients were 
enrolled (Fig. S1 in the Supplementary Appendix). 
A total of 888 patients had at least one stenosis 
with an FFR of 0.80 or less in a large epicardial 
artery: 447 patients were randomly assigned to 
FFR-guided PCI plus the best available medical 
therapy, and 441 patients to the best available 
medical therapy alone. In 332 patients with an-
giographically significant stenoses, none of the 
stenoses had an FFR of 0.80 or less; these patients 
were enrolled in the registry and received the 
best available medical therapy alone. The mean 
(±SD) duration of follow-up was 213±128 days 
among patients assigned to PCI plus the best 
medical available therapy, 214±127 days among 
patients assigned to the best available medical 
therapy alone, and 206±119 days among patients 
enrolled in the registry.
Baseline Characteristics
Table 1 shows the baseline clinical, angiographic, 
and FFR characteristics of the patients who under-
Table 1. (Continued.)
Variable Randomly Assigned Groups Registry Cohort P Value†
PCI plus Medical 
Therapy
Medical Therapy 
Alone
Lesion characteristics
Total no. of lesions 890 815 241
Angiographic findings
Lesions with stenosis of >50% of diameter — no. (%) 837 (94.0) 764 (93.7) 219 (90.9) 0.13
Stenosis — no. (%) <0.001
<50% of diameter 53 (6.0) 51 (6.3) 22 (9.1)
50–69% of diameter 317 (35.6) 331 (40.6) 176 (73.0)
70–90% of diameter 383 (43.0) 331 (40.6) 38 (15.8)
>90% of diameter 101 (11.3) 80 (9.8) 0
Total occlusion 36 (4.0) 22 (2.7) 5 (2.1)
FFR findings
Lesions with FFR ≤0.80 — no. (%) 679 (76.3) 625 (76.7) 5 (2.1)‖ <0.001
Mean FFR in lesions with FFR ≤0.80 0.68±0.10 0.68±0.15 0.50±0.00 0.01
* Plus–minus values are means ±SD. There were no significant differences between the two randomly assigned groups in any of the baseline charac-
teristics, with the exception of left ventricular ejection fraction of less than 50% (P = 0.04). PCI denotes percutaneous coronary intervention.
† The P values are for the combined groups that underwent randomization (the group assigned to PCI plus the best available medical therapy 
and the group assigned to the best available medical therapy alone) as compared with the group of patients who did not undergo random-
ization (patients in whom all stenoses had an FFR of more than 0.80) and were enrolled in a registry. In patient-level analyses, the P values 
were calculated with the use of a chi-square test except when cell numbers were small (<15 patients), in which case Fisher’s exact test was 
used. In lesion-level analyses, mixed maximum-likelihood logistic-regression models were used for between-group comparisons of dichoto-
mous variables, and mixed maximum-likelihood linear-regression models were used for comparisons of continuous variables, to account for 
the correlation of multiple lesions within patients.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Renal insufficiency was defined as a creatinine level of more than 2.0 mg per deciliter (176.8 μmol per liter).
¶ Angina was classified according to the Canadian Cardiovascular Society (CCS) functional classification, in which classes range from I to IV, 
with higher classes indicating greater limitations on physical activity owing to angina.
‖ Five totally occluded arteries supplied infarcted areas and were therefore not considered for revascularization by means of PCI.
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went randomization, as compared with the pa-
tients who were enrolled in the registry. There were 
higher percentages of men, patients with periph-
eral vascular disease, and patients with multivessel 
disease in the groups that underwent randomiza-
tion than in the registry cohort. More than 25% of 
the patients had diabetes, and 68% of the patients 
had angina of class II to IV on the Canadian Car-
diovascular Society (CCS) scale (which ranges from 
I to IV, with higher classes indicating greater 
limitations on physical activity owing to angina). 
There were more lesions per patient and more 
lesions with stenosis of more than 70% of the 
diameter of the artery among patients who under-
went randomization than among patients in the 
registry. A total of 1601 stenoses in the patients 
who underwent randomization were considered 
for PCI on the basis of angiographic findings, 
whereas 1304 were considered for PCI on the ba-
sis of an FFR of 0.80 or less. Among the latter, the 
FFR ranged from 0.19 to 0.80. Table S1 in the 
Supplementary Appendix shows the medications 
the patients were taking at baseline and during 
the follow-up period.
Primary End Point
By January 15, 2012, a total of 75 patients in the 
randomized groups had had at least one primary 
end-point event. The percentage of patients who 
had a primary end-point event was lower in the PCI 
group than in the medical-therapy group (4.3% vs. 
12.7%; hazard ratio with PCI, 0.32; 95% confi-
dence interval [CI], 0.19 to 0.53; P<0.001) (Fig. 1A 
and Table 2). In the registry cohort, 5 patients had 
at least one primary end-point event (3.0%). There 
was little difference in the incidence of a primary 
end-point event between patients in the PCI group 
and patients in the registry (hazard ratio for the 
PCI group, 1.29; 95% CI, 0.49 to 3.39; P = 0.61), 
but there was a large difference between patients 
in the medical-therapy group and patients in the 
registry (hazard ratio for the medical-therapy 
group, 4.32; 95% CI, 1.75 to 10.66; P = 0.001) (Table 
S2 in the Supplementary Appendix).
Secondary End Points
The Kaplan–Meier curves for the individual com-
ponents of the primary end point are shown in 
Figures 1B, 1C, and 1D. Neither the rate of death 
from any cause nor the rate of myocardial infarc-
tion differed significantly between the PCI group 
and the medical-therapy group, but the rate of ur-
gent revascularization did differ significantly be-
tween the groups (hazard ratio with PCI, 0.13; 95% 
CI, 0.06 to 0.30; P<0.001). Among the 56 patients 
who underwent urgent revascularization, the pro-
cedure was triggered by a myocardial infarction 
in 12 patients (21.4%), by unstable angina accom-
panied by evidence of ischemia on ECG in 15 pa-
tients (26.8%), and by unstable angina diagnosed 
on the basis of clinical features in 29 patients 
(51.8%). In an exploratory analysis, 4 patients in 
the PCI group (0.9%) and 23 patients in the med-
ical-therapy group (5.2%) underwent an urgent 
revascularization that was triggered by a myocar-
dial infarction or by unstable angina with evi-
dence of ischemia on ECG (hazard ratio with 
PCI, 0.13; 95% CI, 0.04 to 0.43; P<0.001). As com-
pared with patients in the medical-therapy group, 
patients in the PCI group were significantly less 
likely to undergo any revascularization (hazard 
ratio with PCI, 0.14; 95% CI, 0.08 to 0.26) or non-
urgent revascularization (hazard ratio, 0.17; 95% 
CI, 0.08 to 0.39) (Table 2, and Fig. S2 in the Sup-
plementary Appendix). Among patients in the 
registry, the rates of death from any cause, myo-
cardial infarction, urgent revascularization, and 
nonurgent revascularization were all low (Fig. 1, 
and Table S2 in the Supplementary Appendix).
Figure 2 shows the results from landmark 
analyses of the primary end point and its com-
ponents. PCI plus the best available medical thera-
py was shown to be consistently more beneficial 
after the landmark point of 7 days after random-
ization than before; there were significant inter-
actions between time and treatment with respect 
to the primary end point, the individual compo-
nents of death and myocardial infarction, and 
the composite of death or myocardial infarction, 
as well as a trend toward an interaction with re-
spect to urgent revascularization. Corresponding 
Kaplan–Meier curves are presented in Figure S3 in 
the Supplementary Appendix. Stratified analyses 
according to patient characteristics are shown in 
Figure S4 in the Supplementary Appendix. Effects 
were similar across most subgroups; however, the 
benefit of PCI appeared to be more pronounced 
among patients who had lesions with an FFR of 
less than 0.65 than among patients who had only 
lesions with larger FFR values (P = 0.01 for the in-
teraction). The reduction from baseline in the per-
centage of patients with angina of CCS grade II to 
IV was greater in the PCI group than in the medi-
cal-therapy group and the registry cohort (Fig. 3).
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Discussion
In the FAME 2 trial, we compared the treatment 
strategy of PCI, performed according to current 
quality standards, plus the best available medical 
therapy with the best available medical therapy 
alone in patients with stable coronary artery dis-
ease and hemodynamically significant stenoses. 
FFR-guided PCI with drug-eluting stents plus the 
best available medical therapy, as compared with 
the best available medical therapy alone, resulted 
in significantly improved clinical outcomes. The 
difference between the two strategies was driven 
by an increase by a factor of 8 in the need for 
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Figure 1. Cumulative Incidence of the Primary End Point and Its Components.
Kaplan–Meier curves are shown for the cumulative incidence of the primary end point of death, myocardial infarction, or urgent revascu-
larization (Panel A) and the individual components of the primary end point (Panels B, C, and D) in the group that was randomly assigned 
to PCI and the best available medical therapy (PCI), the group that was randomly assigned to the best available medical therapy alone 
(medical therapy), and the group that did not undergo randomization and was enrolled in a registry (registry). After 12 months, a total  
of two primary end-point events occurred in the PCI group, none in the medical-therapy group, and one in the registry cohort. No deaths 
occurred after 12 months in any of the groups. Two patients in the PCI group, none in the medical-therapy group, and one in the registry 
cohort had a myocardial infarction after 12 months. One patient in the registry cohort, and none in the other two groups, had an urgent 
revascularization performed after 12 months.
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urgent revascularization in the medical-therapy 
group. In the case of half of these urgent revas-
cularizations, the need for the procedure was 
triggered by an increase in biomarker levels, 
ischemic changes on ECG, or both. When we 
performed a landmark analysis, we found that 
the strategy of PCI plus the best available medical 
therapy was more beneficial 8 days or more after 
randomization than 7 days or less after random-
ization, with interactions between time and 
treatment with respect to the primary end point, 
as well as with respect to death and myocardial 
infarction, suggesting that the benefit of PCI 
plus the best available medical therapy might be-
come more pronounced with an increasing dura-
tion of follow-up. The percentage of patients with 
angina of CCS class II to IV was markedly lower 
among patients in the PCI group than among 
patients in the medical-therapy group. Moreover, 
in 25% of the patients in whom PCI was consid-
ered, none of the stenoses that were visible on an 
angiogram were hemodynamically significant as 
assessed by means of the measurement of FFR. 
Among these patients, the strategy of providing 
the best available medical therapy alone was as-
sociated with a very low event rate.
Several factors may explain the differences be-
tween results in the present study and those in 
previous trials involving patients with stable coro-
nary disease.3,4 First, in previous trials in which 
various revascularization methods were com-
pared with the best available medical therapy, 
patient enrollment was based primarily on an-
giographic findings, with or without noninva-
sive documentation of ischemia. It is likely that 
a sizable proportion of the patients had only 
limited ischemia. Even in the Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug 
Evaluation (COURAGE) trial, in which noninvasive 
testing was performed in 85% of the patients,3 
less than one third of the patients had more than 
10% ischemia on myocardial perfusion imag-
ing.8 In daily clinical practice, less than half of 
patients undergo noninvasive stress testing be-
fore elective PCI.22 In the current trial, all the 
patients who underwent randomization had at 
least one functionally significant stenosis. More-
over, a mean FFR value of 0.68 in large epicar-
dial arteries suggests that there were large areas 
of myocardium that were at risk for ischemia. The 
low-risk patients with nonischemic FFR values 
were not randomly assigned to a study group but 
were followed in a registry — a study design that 
was unlike that of previous trials.
Second, among patients in the PCI group who 
had several stenoses, PCI was performed only in 
Table 2. Clinical Events.
Event Randomly Assigned Groups
Registry Cohort 
(N = 166)
PCI plus Medical 
Therapy
(N = 447)
Medical Therapy 
Alone
(N = 441)
Hazard Ratio  
with PCI
(95% CI) P Value
no. (%) no. (%)
Primary end point 19 (4.3) 56 (12.7) 0.32 (0.19–0.53) <0.001 5 (3.0)
Components of primary end point
Death from any cause 1 (0.2) 3 (0.7) 0.33 (0.03–3.17) 0.31 0
Myocardial infarction 15 (3.4) 14 (3.2) 1.05 (0.51–2.19) 0.89 3 (1.8)
Urgent revascularization 7 (1.6) 49 (11.1) 0.13 (0.06–0.30) <0.001 4 (2.4)
Death or myocardial infarction 15 (3.4) 17 (3.9) 0.61 (0.28–1.35) 0.22 3 (1.8)
Cardiac death 1 (0.2) 1 (0.2) 0.96 (0.06–15.17) 0.98 0
Revascularization
Any 14 (3.1) 86 (19.5) 0.14 (0.08–0.26) <0.001 6 (3.6)
Nonurgent revascularization 7 (1.6) 38 (8.6) 0.17 (0.08–0.39) <0.001 2 (1.2)
Stroke 1 (0.2) 2 (0.5) 0.49 (0.04–5.50) 0.56 1 (0.6)
Definite or probable stent thrombosis 5 (1.1) 1 (0.2) 4.98 (0.59–42.25) 0.10 1 (0.6)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on October 30, 2012. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Fr actional Flow Reserve in Stable Coronary Disease
n engl j med 367;11 nejm.org september 13, 2012 999
lesions with an FFR of 0.80 or less. This FFR-
guided approach is associated with a better clini-
cal outcome than that with PCI performed on 
the basis of angiographic results alone.10 These 
features probably explain the similarity of event 
rates between patients who were treated with 
PCI plus the best available medical therapy and 
patients with equivalent baseline characteristics 
but no functionally significant lesions who were 
enrolled in the registry and treated with the best 
available medical therapy alone.
Third, we used drug-eluting stents in patients 
who underwent PCI, a strategy that resulted in a 
low number of repeat revascularizations.18-20 The 
use of anti-ischemic medication was similar to 
that reported in the COURAGE trial23 and was 
most likely much higher than that in routine 
clinical practice.24 Nevertheless, receipt of the best 
available medical therapy did not preclude a sig-
nificantly higher number of unplanned hospi-
talizations with urgent revascularization among 
patients randomly assigned to the best avail-
able medical therapy alone than among those 
assigned to PCI plus the best available medical 
therapy.
Finally, the primary end point of the present 
study included not only death and myocardial 
infarction but also urgent revascularization, a 
component that was not included in the primary 
end point of previous trials. The definition of 
urgent revascularization was stringent in order 
to distinguish it from nonurgent — albeit clini-
cally justified — revascularizations. Among pa-
tients who underwent urgent revascularization, 
the clinical presentation met the criteria of an 
acute coronary syndrome as assessed by an inde-
pendent clinical events committee whose mem-
bers were unaware of the treatment assignments. 
In half the patients who underwent an urgent 
revascularization, the unstable nature of the symp-
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Figure 2. Landmark Analysis of the Primary End Point and Its Components.
The relative risk of the primary end point of death, myocardial infarction, or urgent revascularization and of components of the primary 
end point are shown, according to the time from randomization (7 days or less vs. 8 days or more). The solid boxes represent relative-
risk estimates for 7 days or less after randomization, and the open boxes represent relative-risk estimates for 8 days to the maximum fol-
low-up. Arrows indicate that the lower end of the confidence interval is less than 0.1. (The lower end of the confidence interval for urgent 
revascularization at 8 days to maximum follow-up, which could not be shown on the plot, was 0.04.) P values were calculated with the 
use of a log-rank test, except for the following, which were calculated with the use of Fisher’s exact test: death or myocardial infarction at 
7 days or less; death at 8 days to maximum follow-up; myocardial infarction at 7 days or less; and urgent revascularization at 7 days or 
less. P values for the interaction between time and treatment with respect to the end points were calculated with the use of the Mantel–
Cox method. A total of 10 patients randomly assigned to PCI plus the best available medical therapy and 8 patients assigned to the best 
available medical therapy alone underwent randomization during the week before January 15, 2012, and their data were censored for the 
analysis of 8 days to maximum follow-up. In addition, 1 patient in each of those groups withdrew consent during the first week of follow-
up, and their data were also censored in the analysis of the subsequent period.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on October 30, 2012. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;11 nejm.org september 13, 20121000
toms was evidenced by ST-segment depression, 
biomarker elevation, or both. The occurrence of 
an acute coronary syndrome necessitates hospi-
talization and is associated with an unfavorable 
prognosis, and it should therefore be considered 
to be a treatment failure. More important, revas-
cularization has been shown to improve the rate 
of survival and decrease the risk of myocardial 
infarction among high-risk patients with an acute 
coronary syndrome.25-27
The trial has several limitations. First, because 
of the premature termination of enrollment, there 
was an unusually short follow-up period — too 
short to see restenosis emerge as a complication 
of PCI. Differences in the rates of death and 
myocardial infarction between the strategies of 
PCI and medical therapy alone that were seen in 
one recent registry study28 could not be confirmed. 
However, the difference in the primary outcome 
between the two treatment groups was large and 
was steadily increasing over time; therefore, the 
data and safety monitoring board believed that 
exposing more patients with functionally signifi-
cant stenoses to the risk of urgent revasculariza-
tion was inappropriate. Second, although random-
ization was concealed,29 it is possible that the 
awareness of the presence of a stenosis influ-
enced decisions regarding revascularization. Third, 
even though the adherence to medications was 
high, the best available medical therapy did not 
include interventions by nurse case managers that 
were aimed at lifestyle changes and risk-factor 
reduction, interventions that were included as 
part of the best available medical therapy in the 
COURAGE trial.23 Fourth, the strategic nature of 
the trial meant that we followed contemporary 
guidelines,30 which require dual antiplatelet treat-
ment only for patients who undergo stenting. It 
is unlikely that this difference in drug regimen 
between the two groups could explain the mag-
nitude of the observed difference with respect to 
the primary end point.
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Figure 3. Patients with Angina Class II to IV and Corresponding Relative Risks.
The percentage of patients with angina of class II to IV on the Canadian Cardiovascular Society (CCS) scale (which ranges from I to IV, 
with higher classes indicating greater limitations on physical activity owing to angina) and the corresponding relative risks are shown at 
various time points for the group that was randomly assigned to PCI and the best available medical therapy (PCI), the group that was 
randomly assigned to the best available medical therapy alone (medical therapy), and the group that did not undergo randomization and 
was enrolled in a registry (registry). A total of 414 patients in the PCI group, 417 in the medical-therapy group, and 151 in the registry cohort 
were eligible for follow-up at 30 days; the corresponding numbers at 6 months were 238, 241, and 92, and the corresponding numbers at 
1 year were 41, 38, and 7.
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In conclusion, among patients with stable coro-
nary artery disease and at least one stenosis with 
an FFR of 0.80 or less, FFR-guided PCI with drug-
eluting stents plus the best available medical ther-
apy, as compared with the best available medical 
therapy alone, decreased the rate of urgent re-
vascularization. Among patients with stenoses 
that were not functionally significant, the best 
available medical therapy alone resulted in an 
excellent outcome, regardless of the angiographic 
appearance of the stenoses.
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